ICUI Stock Recent News
ICUI LATEST HEADLINES
SAN CLEMENTE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2025 earnings release and conference call.
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / May 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc. (“ICU” or the “Company”) (NASDAQ: ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc. ("ICU" or the "Company") (NASDAQ: ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc. (“ICU” or the “Company”) (NASDAQ: ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.